{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:16:46Z","timestamp":1790115406646,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Persistent airflow limitation and dyspnoea may reduce chronic obstructive pulmonary disease (COPD) patients exercise capacity and physical activity, undermining their physical status and quality of life. Long-acting muscarinic antagonists and long-acting beta-2 agonists (LAMA\/LABA) combinations are amongst moderate-to-severe COPD recommended treatments. This article analyses LAMA\/LABA combinations effect on COPD patients exercise capacity and physical activity outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review and meta-analysis of double-blind randomized controlled trials comparing LAMA\/LABA combinations against monotherapy or placebo was conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen articles were identified (N\u2009=\u20094041 patients). In endurance shuttle walk test and constant work rate cycle ergometry, LAMA\/LABA combinations obtained better results than placebo, but not monotherapy, whereas in 6-min walking test, results favoured LAMA\/LABA over monotherapy (four studies), but not over placebo (one study). Moreover, LAMA\/LABA combinations obtained better results than placebo in number of steps per day, reduction in percentage of inactive patients and daily activity-related energy expenditure, and better than monotherapy when measuring time spent on \u2265\u20091.0\u20131.5,\u2009\u2265\u20092.0 and\u2009\u2265\u20093.0 metabolic equivalents of task activities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LAMA\/LABA combinations in COPD patients provided better results than monotherapy or placebo in most exercise capacity and physical activity outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02268-3","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:02:57Z","timestamp":1671084177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Exercise capacity and physical activity in COPD patients treated with a LAMA\/LABA combination: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Lu\u00eds","family":"Garc\u00eda-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Galera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Palomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2268_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of COPD. The Global Initiative for Chronic Obstructive Lung Diseases (GOLD). 2020."},{"key":"2268_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.arbres.2019.06.015","volume":"56","author":"H Tekerlek","year":"2020","unstructured":"Tekerlek H, Cakmak A, Calik-Kutukcu E, Arikan H, Inal-Ince D, Saglam M, et al. Exercise capacity and activities of daily living are related in patients with chronic obstructive pulmonary disease. Arch Bronconeumol. 2020;56:208\u201313.","journal-title":"Arch Bronconeumol"},{"key":"2268_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1378\/chest.10-2521","volume":"140","author":"B Waschki","year":"2011","unstructured":"Waschki B, Kirsten A, Holz O, M\u00fcller K-C, Meyer T, Watz H, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD. Chest. 2011;140:331\u201342.","journal-title":"Chest"},{"key":"2268_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/15412555.2021.1937090","volume":"18","author":"L Mendoza","year":"2021","unstructured":"Mendoza L, de Oca MM, L\u00f3pez Varela MV, Casas A, Ram\u00edrez-Venegas A, L\u00f3pez A, et al. Physical activity levels and associated factors in a Latin American COPD population of patients. The LASSYC Study. COPD J Chronic Obstr Pulmon Dis. 2021;18:393.","journal-title":"COPD J Chronic Obstr Pulmon Dis."},{"key":"2268_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1164\/rccm.200812-1873OC","volume":"180","author":"F Garcia-Rio","year":"2009","unstructured":"Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, L\u00f3pez-Collazo E, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med. 2009;180:506\u201312.","journal-title":"Am J Respir Crit Care Med"},{"key":"2268_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12931-018-0721-3","volume":"19","author":"F di Marco","year":"2018","unstructured":"di Marco F, Sotgiu G, Santus P, O\u2019Donnell DE, Beeh K-M, Dore S, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018;19:18.","journal-title":"Respir Res"},{"key":"2268_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.chest.2018.02.023","volume":"154","author":"A Anzueto","year":"2018","unstructured":"Anzueto A, Miravitlles M. Considerations for the correct diagnosis of COPD and its management with bronchodilators. Chest. 2018;154:242\u20138.","journal-title":"Chest"},{"key":"2268_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.rmed.2015.03.010","volume":"109","author":"A Rossi","year":"2015","unstructured":"Rossi A, Aisanov Z, Avdeev S, di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785\u2013802.","journal-title":"Respir Med"},{"key":"2268_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"2268_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1183\/09031936.00183014","volume":"46","author":"E Gimeno-Santos","year":"2015","unstructured":"Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J. 2015;46:988\u20131000.","journal-title":"Eur Respir J"},{"key":"2268_CR11","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV. Cochrane Handbook for Systematic Reviews of Interventions version 6.1. 2020.","DOI":"10.1002\/9781119536604"},{"key":"2268_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1164\/rccm.201706-1288OC","volume":"198","author":"T Troosters","year":"2018","unstructured":"Troosters T, Maltais F, Leidy N, Lavoie KL, Sedeno M, Janssens W, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:1021\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"2268_CR13","doi-asserted-by":"publisher","first-page":"1601348","DOI":"10.1183\/13993003.01348-2016","volume":"49","author":"DE O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell DE, Casaburi R, Frith P, Kirsten A, de Sousa D, Hamilton A, et al. Effects of combined tiotropium\/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49:1601348.","journal-title":"Eur Respir J"},{"key":"2268_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2147\/COPD.S166023","volume":"13","author":"M Ichinose","year":"2018","unstructured":"Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, et al. Efficacy of tiotropium\/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis. 2018;13:1407\u201319.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2147\/COPD.S143488","volume":"12","author":"H Watz","year":"2017","unstructured":"Watz H, Troosters T, Beeh KM, Garcia Aymerich J, Paggiaro P, Molins E, et al. ACTIVATE: the effect of aclidinium\/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545\u201358.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR16","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/COPD.S208081","volume":"14","author":"Y Minakata","year":"2019","unstructured":"Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, et al. Effect of tiotropium\/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO\u00ae study. Int J Chron Obstruct Pulmon Dis. 2019;14:1789\u2013801.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/COPD.S145285","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, et al. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:203\u201315.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR18","doi-asserted-by":"publisher","first-page":"00073","DOI":"10.1183\/23120541.00073-2017","volume":"4","author":"JH Riley","year":"2018","unstructured":"Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L. Effects of umeclidinium\/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Res. 2018;4:00073\u20132017.","journal-title":"ERJ Open Res"},{"key":"2268_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.resp.2017.10.001","volume":"247","author":"DE O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell DE, Elbehairy AF, Faisal A, Neder JA, Webb KA. Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD. Respir Physiol Neurobiol. 2018;247:116\u201325.","journal-title":"Respir Physiol Neurobiol"},{"key":"2268_CR20","doi-asserted-by":"publisher","first-page":"175346581875509","DOI":"10.1177\/1753465818755091","volume":"12","author":"F Maltais","year":"2018","unstructured":"Maltais F, O\u2019Donnell D, G\u00e1ldizIturri JB, Kirsten A-M, Singh D, Hamilton A, et al. Effect of 12 weeks of once-daily tiotropium\/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:175346581875509.","journal-title":"Ther Adv Respir Dis"},{"key":"2268_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12890-016-0256-7","volume":"16","author":"H Watz","year":"2016","unstructured":"Watz H, Mail\u00e4nder C, Baier M, Kirsten A. Effects of indacaterol\/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulm Med. 2016;16:95.","journal-title":"BMC Pulm Med"},{"key":"2268_CR22","doi-asserted-by":"publisher","first-page":"175346662092685","DOI":"10.1177\/1753466620926858","volume":"14","author":"F Maltais","year":"2020","unstructured":"Maltais F, O\u2019Donnell DE, Hamilton A, Zhao Y, Casaburi R. Comparative measurement properties of constant work rate cycling and the endurance shuttle walking test in COPD: the TORRACTO\u00ae clinical trial. Ther Adv Respir Dis. 2020;14:175346662092685.","journal-title":"Ther Adv Respir Dis"},{"key":"2268_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.rmed.2012.05.012","volume":"106","author":"ND Canto","year":"2012","unstructured":"Canto ND, Ribeiro JP, Neder JA, Chiappa GR. Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD. Respir Med. 2012;106:1404\u201312.","journal-title":"Respir Med"},{"key":"2268_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/15412555.2013.771162","volume":"10","author":"L Jayaram","year":"2013","unstructured":"Jayaram L, Wong C, McAuley S, Rea H, Zeng I, O\u2019Dochartaigh C. Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6-minute walk test. COPD J Chron Obstruct Pulmon Dis. 2013;10:466\u201372.","journal-title":"COPD J Chron Obstruct Pulmon Dis."},{"key":"2268_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2147\/COPD.S268905","volume":"15","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, et al. First-line treatment with tiotropium\/olodaterol improves physical activity in patients with treatment-na\u00efve chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:2115\u201326.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR26","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1152\/japplphysiol.00774.2020","volume":"130","author":"WW Stringer","year":"2021","unstructured":"Stringer WW, Porszasz J, Cao M, Rossiter HB, Siddiqui S, Rennard S, et al. The effect of long-acting dual bronchodilator therapy on exercise tolerance, dynamic hyperinflation, and dead space during constant work rate exercise in COPD. J Appl Physiol. 2021;130:2009\u201318.","journal-title":"J Appl Physiol"},{"key":"2268_CR27","doi-asserted-by":"publisher","first-page":"175346662110374","DOI":"10.1177\/17534666211037454","volume":"15","author":"E Tufvesson","year":"2021","unstructured":"Tufvesson E, Radner F, Simonsen A, Papapostolou G, Jarenb\u00e4ck L, J\u00f6nsson S, et al. A new protocol for exercise testing in COPD; improved prediction algorithm for W MAX and validation of the endurance test in a placebo-controlled double bronchodilator study. Ther Adv Respir Dis. 2021;15:17534666211037454.","journal-title":"Ther Adv Respir Dis."},{"key":"2268_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1753465814559209","volume":"8","author":"F Maltais","year":"2014","unstructured":"Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. Effects of a combination of umeclidinium\/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8:169\u201381.","journal-title":"Ther Adv Respir Dis"},{"key":"2268_CR29","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:e56-69.","journal-title":"Am J Respir Crit Care Med"},{"key":"2268_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.amjmed.2017.12.018","volume":"131","author":"A Anzueto","year":"2018","unstructured":"Anzueto A, Miravitlles M. The role of fixed-dose dual bronchodilator therapy in treating COPD. Am J Med. 2018;131:608\u201322.","journal-title":"Am J Med"},{"key":"2268_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00408-014-9557-x","volume":"192","author":"M Miravitlles","year":"2014","unstructured":"Miravitlles M, Cantoni J, Naberan K. Factors associated with a low level of physical activity in patients with chronic obstructive pulmonary disease. Lung. 2014;192:259\u201365.","journal-title":"Lung"},{"key":"2268_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.arbres.2020.08.001","volume":"57","author":"M Koreny","year":"2021","unstructured":"Koreny M, Demeyer H, Benet M, Arbillaga-Etxarri A, Balcells E, Barberan-Garcia A, et al. Patterns of physical activity progression in patients with COPD. Arch Bronconeumol. 2021;57:214\u201323.","journal-title":"Arch Bronconeumol"},{"key":"2268_CR33","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1249\/MSS.0000000000001859","volume":"51","author":"H Demeyer","year":"2019","unstructured":"Demeyer H, Donaire-Gonzalez D, Gimeno-Santos E, Ramon MA, de Battle J, Benet M, et al. Physical activity is associated with attenuated disease progression in chronic obstructive pulmonary disease. Med Sci Sports Exerc. 2019;51:833\u201340.","journal-title":"Med Sci Sports Exerc"},{"key":"2268_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1164\/rccm.201501-0081OC","volume":"192","author":"B Waschki","year":"2015","unstructured":"Waschki B, Kirsten AM, Holz O, Mueller K-C, Schaper M, Sack A-L, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:295\u2013306.","journal-title":"Am J Respir Crit Care Med"},{"key":"2268_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12931-020-1290-9","volume":"21","author":"NA Sievi","year":"2020","unstructured":"Sievi NA, Brack T, Brutsche MH, Frey M, Irani S, Leuppi JD, et al. \u201cCan do, don\u2019t do\u201d are not the lazy ones: a longitudinal study on physical functioning in patients with COPD. Respir Res. 2020;21:27.","journal-title":"Respir Res"},{"key":"2268_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2147\/COPD.S103023","volume":"11","author":"T Glaab","year":"2016","unstructured":"Glaab T, Sauer R, H\u00e4nsel M, Rubin RA, Frey M, Buhl R. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis. 2016;11:891.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"2268_CR37","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2147\/COPD.S195852","volume":"14","author":"K-O Steinmetz","year":"2019","unstructured":"Steinmetz K-O, Abenhardt B, Pabst S, H\u00e4nsel M, Kondla A, Bayer V, et al. Assessment of physical functioning and handling of tiotropium\/olodaterol Respimat\u00ae in patients with COPD in a real-world clinical setting. Int J Chron Obstruct Pulmon Dis. 2019;14:1441\u201353.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR38","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.2147\/COPD.S204388","volume":"14","author":"A Valipour","year":"2019","unstructured":"Valipour A, Tamm M, Koci\u00e1nov\u00e1 J, Bayer V, Sanzharovskaya M, Medvedchikov A, et al. Improvement in self-reported physical functioning with tiotropium\/olodaterol in central and Eastern European COPD Patients. Int J Chron Obstruct Pulmon Dis. 2019;14:2343\u201354.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.semerg.2020.10.006","volume":"47","author":"J Molina Par\u00eds","year":"2020","unstructured":"Molina Par\u00eds J, Alonso Hern\u00e1ndez PM, D\u00edez Garc\u00eda JA, Gonzalez Uribe-Etxebarria I, Yelo Garc\u00eda J, Galera Llorca J, et al. Assessment of physical functioning in patients with chronic obstructive pulmonary disease (COPD) requiring long-acting dual bronchodilation in routine clinical practice. Med Familia Semergen. 2020;47:295.","journal-title":"Med Familia Semergen."},{"key":"2268_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s41030-020-00122-9","volume":"6","author":"M Carone","year":"2020","unstructured":"Carone M, Pennisi A, D\u2019Amato M, Donati AF, Ricci A, Scognamillo C, et al. Physical functioning in patients with chronic obstructive pulmonary disease treated with tiotropium\/olodaterol respimat in routine clinical practice in Italy. Pulm Ther. 2020;6:261\u201374.","journal-title":"Pulm Ther"},{"key":"2268_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.14740\/jocmr4542","volume":"13","author":"M Spielmanns","year":"2021","unstructured":"Spielmanns M, Tamm M, Schildge S, Valipour A. Swiss experience in therapy with dual bronchodilation in chronic obstructive pulmonary disease in relation to self-reported physical functionality. J Clin Med Res. 2021;13:392\u2013402.","journal-title":"J Clin Med Res"},{"key":"2268_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.06.020","volume":"129","author":"L Calzetta","year":"2017","unstructured":"Calzetta L, Ora J, Cavalli F, Rogliani P, O\u2019Donnell DE, Cazzola M. Impact of LABA\/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis. Respir Med. 2017;129:189\u201398.","journal-title":"Respir Med"},{"key":"2268_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1513\/pats.201201-014ST","volume":"9","author":"L Nici","year":"2012","unstructured":"Nici L, ZuWallack R. An official American Thoracic Society workshop report: the integrated care of the COPD patient. Proc Am Thorac Soc. 2012;9:9\u201318.","journal-title":"Proc Am Thorac Soc"},{"key":"2268_CR44","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1164\/rccm.201309-1634ST","volume":"188","author":"MA Spruit","year":"2013","unstructured":"Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An Official American Thoracic Society\/European Respiratory Society Statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-64.","journal-title":"Am J Respir Crit Care Med"},{"key":"2268_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","volume":"58","author":"M Miravitlles","year":"2022","unstructured":"Miravitlles M, Calle M, Molina J, Almagro P, G\u00f3mez J-T, Trigueros JA, et al. Spanish COPD Guidelines (GesEPOC) 2021: updated Pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58:69\u201381.","journal-title":"Arch Bronconeumol"},{"key":"2268_CR46","doi-asserted-by":"crossref","unstructured":"Cos\u00edo BG, Hern\u00e1ndez C, Chiner E, Gimeno-Santos E, Pleguezuelos E, Seijas N, et al. [Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. Arch Bronconeumol. 2022;58:345\u201351.","DOI":"10.1016\/j.arbres.2021.08.024"},{"key":"2268_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12325-020-01557-x","volume":"38","author":"F Maltais","year":"2021","unstructured":"Maltais F, de la Hoz A, Casaburi R, O\u2019Donnell D. Effects of tiotropium\/olodaterol on activity-related breathlessness, exercise endurance and physical activity in patients with COPD: narrative review with meta-\/pooled analyses. Adv Ther. 2021;38:835\u201353.","journal-title":"Adv Ther"},{"key":"2268_CR48","doi-asserted-by":"publisher","first-page":"170125","DOI":"10.1183\/16000617.0125-2017","volume":"27","author":"EFM Wouters","year":"2018","unstructured":"Wouters EFM, Wouters BBREF, Augustin IML, Houben-Wilke S, Vanfleteren LEGW, Franssen FME. Personalised pulmonary rehabilitation in COPD. Eur Respir Rev. 2018;27:170125.","journal-title":"Eur Respir Rev"},{"key":"2268_CR49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1164\/rccm.201603-0602OC","volume":"195","author":"M-R G\u00fcell","year":"2017","unstructured":"G\u00fcell M-R, Cejudo P, Ortega F, Puy MC, Rodr\u00edguez-Trigo G, Pijoan JI, et al. Benefits of long-term pulmonary rehabilitation maintenance program in patients with severe chronic obstructive pulmonary disease. Three-year follow-up. Am J Respir Crit Care Med. 2017;195:622\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2268_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00408-015-9838-z","volume":"194","author":"E Pleguezuelos","year":"2016","unstructured":"Pleguezuelos E, Esquinas C, Moreno E, Guirao L, Ortiz J, Garcia-Alsina J, et al. Muscular dysfunction in COPD: systemic effect or deconditioning? Lung. 2016;194:249\u201357.","journal-title":"Lung"},{"key":"2268_CR51","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/COPD.S246571","volume":"15","author":"Z Matkovic","year":"2020","unstructured":"Matkovic Z, Tudoric N, Cvetko D, Esquinas C, Rahelic D, Zarak M, et al. Easy to perform physical performance tests to identify COPD patients with low physical activity in clinical practice. Int J Chron Obstruct Pulmon Dis. 2020;15:921\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2268_CR52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.15326\/jcopdf.2021.0213","volume":"8","author":"H Demeyer","year":"2021","unstructured":"Demeyer H, Mohan D, Burtin C, Vaes A, Heasley M, Bowler RP, et al. Objectively measured physical activity in patients with COPD: recommendations from an international task force on physical activity. Chron Obstruct Pulmon Dis J COPD Found. 2021;8:528\u201350.","journal-title":"Chron Obstruct Pulmon Dis J COPD Found"},{"key":"2268_CR53","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2147\/COPD.S70518","volume":"10","author":"I Fotheringham","year":"2015","unstructured":"Fotheringham I, Meakin G, Punekar Y, Riley J, Cockle S, Singh S. Comparison of laboratory- and field-based exercise tests for COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2015;10:625.","journal-title":"Int J Chron Obstruct Pulmon Dis."}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02268-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T07:09:57Z","timestamp":1671088197000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02268-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2268"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02268-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols and research grants from Grifols. Juan Luis Garc\u00eda-Rivero has received speaker fees from Novartis, GSK, Boehringer-Ingelheim, Astra-Zeneca, Chiesi, ALK, Teva, Menarini, Viso and Sanofi; and consulting fees from Novartis, GSK, Astra-Zeneca, Teva, Boehringer-Ingelheim, ALK, Viso, Gebro and Sanofi. Xavier Pomares has received speaker fees from Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Rovi, Novartis, Vertex and Actelion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"347"}}